Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 188-195

  Foulds, P G ^a   Yokota, O ^b,c   Thurston, A ^b   Davidson, Y ^b   Ahmed, Z ^d   Holton, J ^d   Thompson, J C ^e   Akiyama, H ^f   Arai, T ^f   Hasegawa, M ^f   Gerhard, A ^b   Allsop, D ^a   Mann, D M A ^b  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c OKAYAMA UNIVERSITY   (Japan)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HOPE HOSPITAL   (United Kingdom)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Alpha synuclein; Cerebrospinal fluid; Dementia with Lewy Bodies; Multiple system atrophy; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN;

ADULT; AGED; ALPHA SYNUCLEINOPATHY; ARTICLE; AUTOPSY; BODY FLUID; BRAIN TISSUE; BRAIN VENTRICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SHY DRAGER SYNDROME; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; BRAIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE;

EID: 81955167983     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.08.003     Document Type: Article

References (33)

1. Aerts, M.B., et al., in press. CSF α-synuclein does not discriminate between parkinsonian disorders. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2010.12.001.
2. Angot E., Brundin P. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S143-S147.
3. Anderson J.P., et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
4. Barbour R., et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 2008, 5:55-59.
5. Blennow K., Hampel H. CSF markers for incipient Alzheimer's Disease. Lancet Neurol. 2003, 2:605-613.
6. El-Agnaf O.M., et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003, 17:1945-1947.
7. El-Agnaf O.M., et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20:419-425.
8. Emmanouilidou E., et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30:6838-6851.
9. Foulds P., et al. Progress towards a molecular biomarker for Parkinson disease. Nat. Rev. Neurol. 2010, 6:359-361.
10. Fujiwara H., et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
11. Hirohata M., et al. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation. Neurosci. Lett. 2011, 491:48-52.
12. Hong Z., et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
13. Hughes A.J., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
14. Hughes A.J., et al. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001, 57:1497-1499.
15. Kasai T., et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009, 117:55-62.
16. Lee H.J., et al. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 2005, 25:6016-6024.
17. Mollenhauer B., et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 2008, 213:315-325.
18. Mollenhauer B., et al. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230-240.
19. Obi K., et al. Relationship of phosphorylated α-synuclein and tau accumulation to Ab deposition in the cerebral cortex of dementia with Lewy bodies. Exp. Neurol. 2008, 210:409-420.
20. Ohrfelt A., et al. Cerebrospinal fluid α-synuclein in neurodegenerative disorders: a marker of synapse loss?. Neurosci. Lett. 2009, 450:332-335.
21. Paleologou K., et al. Detection of elevated levels of soluble {αlph}-synuclein oligomers in post mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132:1093-1101.
22. Poewe W., Wenning G. The differential diagnosis of Parkinson's disease. Eur. J. Neurol. 2002, 9:23-30.
23. Reesink F.E., et al. CSF α-synuclein does not discriminate Dementia with Lewy bodies from Alzheimer's disease. J. Alzheimer's Dis. 2010, 22:87-95.
24. Sasakawa H., et al. Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of α-synuclein. Biochem. Biophys. Res. Commun. 2007, 363:795-799.
25. Schlossmacher M.G., Mollenhauer B. Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. Biomarkers 2010, 4:647-650.
26. Sharon R., et al. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
27. Shi M., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 10.1002/ana.22311.
28. Shults C.W., et al. Alpha-synuclein from platelets is not phosphorylated at serine 129 in Parkinson's disease and multiple system atrophy. Neurosci. Lett. 2006, 25:223-225.
29. Spies P.E., et al. Cerebrospinal alpha synuclein does not discriminate between dementia disorders. J. Alzheimer Dis. 2009, 16:363-369.
30. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
31. Spillantini M.G., et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6469-6473.
32. Tokuda T., et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 349:162-166.
33. Tokuda T., et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.